Cloud-clone
SKU(재고 관리 코드):RAB167Hu21
Recombinant Antibody to Cluster Of Differentiation 4 (CD4)
Recombinant Antibody to Cluster Of Differentiation 4 (CD4)
Western blotting: 1:40-1:400
;Immunohistochemistry: 1:40-1:200
;Immunocytochemistry: 1:40-1:200
;Flow cytometry: 0.2-2µL/106 cells
;Optimal working dilutions must be determined by end user.
Product No.
RAB167Hu21
Organism Species
Homo sapiens (Human).
Source
Recombinant monoclonal antibody preparation
Host
Mouse
Potency (Clone Number)
320,000:1
Ig Isotype
IgG2b Kappa
Purification
Protein A + Protein G affinity chromatography
Label
None
Immunogen
RPB167Hu01-Recombinant Cluster Of Differentiation 4 (CD4)
Buffer Formulation
0.01M PBS, pH7.4, containing 0.05% Proclin-300, 50% glycerol.
Traits
Liquid
Concentration
0.1-1mg/ml
Organism Species More
n/a
Applications
WB; IHC; ICC.
If the antibody is used in flow cytometry, please check FCM antibodies.
UOM
20µl 100µl 200µl 1ml 10ml
SPECIFITY
The antibody is a mouse monoclonal antibody raised against CD4. It has been selected for its ability to recognize CD4 in immunohistochemical staining and western blotting.
USAGE
Western blotting: 0.2-2µg/mL;1:500-5000
Immunohistochemistry: 5-20µg/mL;1:50-200
Immunocytochemistry: 5-20µg/mL;1:50-200
Optimal working dilutions must be determined by end user.
STORAGE
Store at 4°C for frequent use. Stored at -20°C in a manual defrost freezer for two year without detectable loss of activity. Avoid repeated freeze-thaw cycles.
STABILITY
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37°C for 48h, and no obvious degradation and precipitation were observed. The loss rate is less than 5% within the expiration date under appropriate storage condition.
| Magazine | Citations |
| Taylor & Francis | Influences of Hyriopsis cumingii polysaccharides on mice immunosignaling molecules and T lymphocyte differentiation 09540105.2017.1306494 |
| anticancer research | Adjuvant Postoperative CD40 Agonist and PD-1 Antagonist Combination Therapy in Syngeneic Tongue Cancer Mouse Model Pubmed: 32366416 |
Share
